China-based biotech Ascentage Pharma has raised $126m in a US initial public offering (IPO), marking the first biotech IPO of 2025. The company sold 7,325,000 American Depositary shares at $17.25 ...

Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s US trading debut, after pricing its $126.4 million initial public ...

Shares of Ascentage Pharma Group (AAPG) (OTCPK:AAPGV) (OTCPK:ASPHF), which is backed by Takeda (NYSE:TAK), were trading largely flat Friday following the company's $126M U.S. initial public offering.

Takeda-backed Ascentage Pharma Group (AAPG) has filed to raise up to $100M through a U.S. initial public offering. The Chinese drug developer didn't specify terms in its SEC filing, but indicated ...

all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Ascentage Pharma Group International has filed a registration ...

Ascentage aims to raise $149 mln via US IPO Plans to offer 7.3 mln American depositary shares at $20.34 each Company's shares already listed in Hong Kong Jan 21 (Reuters) - Ascentage Pharma (6855 ...

Ascentage Pharma Group International AAPG – up 6.9 ... CTRL Group raised gross proceeds of $8 million from the Offering on Jan. 22. The IPO market shows strong potential for 2025.

Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, raising $126 million for its pipeline of small-molecule cancer drugs.